Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APYXNASDAQ:LQDANASDAQ:PLSENASDAQ:SOLYNASDAQ:XAIR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.33+0.8%$1.72$1.21▼$7.97$46.07M1.09143,975 shs66,146 shsLQDALiquidia$12.62-2.5%$14.64$5.71▼$16.99$959.50M0.16944,445 shs557,827 shsPLSEPulse Biosciences$6.77-1.3%$8.82$3.78▼$13.62$373.84M1.67181,096 shs70,794 shsSOLYSoliton$22.58$21.55$7.40▼$22.60$487.66M0.19347,827 shsN/AXAIRBeyond Air$1.25+3.3%$1.66$1.14▼$6.36$45.05M-0.18305,262 shs235,039 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+4.76%-5.04%+5.60%-39.17%-56.15%LQDALiquidia-1.75%-4.64%-22.59%+7.38%+90.44%PLSEPulse Biosciences+0.15%-11.83%-23.44%-21.15%+19.30%SOLYSoliton0.00%0.00%0.00%0.00%0.00%XAIRBeyond Air0.00%-9.02%-23.42%-11.03%-79.21%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical3.808 of 5 stars3.54.00.04.20.01.70.6LQDALiquidia2.1065 of 5 stars3.31.00.00.01.84.20.6PLSEPulse BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASOLYSolitonN/AN/AN/AN/AN/AN/AN/AN/AXAIRBeyond Air3.1352 of 5 stars3.50.00.03.51.10.81.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical3.00Buy$6.17363.66% UpsideLQDALiquidia2.60Moderate Buy$21.0066.40% UpsidePLSEPulse BiosciencesN/AN/AN/AN/ASOLYSolitonN/AN/AN/AN/AXAIRBeyond Air3.00Buy$11.25800.00% UpsideCurrent Analyst RatingsLatest PLSE, APYX, XAIR, SOLY, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.004/1/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/14/2024LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $32.003/13/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.002/21/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$52.35M0.88N/AN/A$0.78 per share1.71LQDALiquidia$17.49M54.86N/AN/A$0.73 per share17.29PLSEPulse Biosciences$700K534.06N/AN/A$0.81 per share8.36SOLYSolitonN/AN/AN/AN/A$1.46 per shareN/AXAIRBeyond AirN/AN/AN/AN/A$1.40 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)LQDALiquidia-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)PLSEPulse Biosciences-$42.21M-$0.89N/A∞N/AN/A-112.74%-61.09%5/9/2024 (Estimated)SOLYSoliton-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/AXAIRBeyond Air-$55.82M-$2.13N/AN/AN/AN/A-199.90%-106.00%6/27/2024 (Estimated)Latest PLSE, APYX, XAIR, SOLY, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PLSEPulse BiosciencesN/A-$0.21-$0.21-$0.20N/AN/A3/21/2024Q4 2023APYXApyx Medical-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million3/13/2024Q4 2023LQDALiquidia-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million2/12/202412/31/2023XAIRBeyond Air-$0.61-$0.50+$0.11-$0.50$0.49 million$0.39 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ASOLYSolitonN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical1.235.524.74LQDALiquidiaN/A4.854.85PLSEPulse BiosciencesN/A6.766.76SOLYSolitonN/A5.475.37XAIRBeyond Air0.613.393.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%LQDALiquidia64.54%PLSEPulse Biosciences76.95%SOLYSoliton35.11%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical13.10%LQDALiquidia31.60%PLSEPulse Biosciences69.70%SOLYSoliton12.00%XAIRBeyond Air19.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical25234.64 million30.11 millionOptionableLQDALiquidia14576.03 million52.00 millionOptionablePLSEPulse Biosciences6155.22 million16.73 millionOptionableSOLYSoliton1421.60 million19.01 millionNot OptionableXAIRBeyond Air9836.04 million29.19 millionOptionablePLSE, APYX, XAIR, SOLY, and LQDA HeadlinesSourceHeadlineBeyond Paradise's dating storyline is a breath of fresh airdigitalspy.com - April 12 at 6:47 PMBeyond the Horizon Air and Space Show ends with record number of spectatorsmsn.com - April 10 at 1:56 PMBeyond the Horizon Air Show attracts thousands to Maxwell AFBwsfa.com - April 7 at 2:22 PMBeyond Air (NASDAQ:XAIR) Trading 3.2% Higher marketbeat.com - April 5 at 12:43 AMBeyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?zacks.com - March 21 at 1:01 PMBeyond Air Prices Direct Offering Of $16 Mln Of Shares, Warrantsmarkets.businessinsider.com - March 20 at 6:51 PMBeyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrantsglobenewswire.com - March 20 at 9:00 AM"There is a great need to look for mobility alternatives and we are going to operate with electric vehicles in the air"lapoliticaonline.com - March 18 at 11:59 PMBeyond Paradise star teases a different side to her character in season 2yahoo.com - March 16 at 11:37 PMWill Renewed Nvidia Excitement Lift the Entire Market?realmoney.thestreet.com - February 23 at 10:34 AMBed Bath & Beyond has a new CEO, air quality’s rising impact on real estate and moreyahoo.com - February 20 at 5:50 PMBeyond Air (XAIR) Earnings Dates & Reportsinvesting.com - February 13 at 10:29 PMBeyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcriptmsn.com - February 13 at 12:27 PMRecap: Beyond Air Q3 Earningsbenzinga.com - February 12 at 9:23 PMBeyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimatesmsn.com - February 12 at 9:23 PMBeyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024finance.yahoo.com - February 12 at 4:22 PMBeyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024finance.yahoo.com - February 12 at 4:22 PMA Preview Of Beyond Air's Earningsbenzinga.com - February 9 at 2:21 PMAI model gives air quality forecasts that are similar to weather forecastsmsn.com - February 3 at 10:01 PMBeyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcastfinance.yahoo.com - January 18 at 1:43 PMBeyond Air Inc (XAIR) may enjoy gains as insiders got busy in the recent daysknoxdaily.com - January 2 at 12:58 PMMedical Device Player Beyond Air's Subsidiary Reveals Encouraging Data From Early-Stage Cancer Studymsn.com - December 27 at 12:25 PMBeyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumorsfinance.yahoo.com - December 27 at 12:25 PMBeyond Air Independent Director Acquires 102% More Stockfinance.yahoo.com - December 23 at 9:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApyx MedicalNASDAQ:APYXApyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.LiquidiaNASDAQ:LQDALiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Pulse BiosciencesNASDAQ:PLSEPulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.SolitonNASDAQ:SOLYSoliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.Beyond AirNASDAQ:XAIRBeyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.